Muscle Response to High Intensity Interval Resistance Training (HIIRT) (HIIRT)

March 24, 2020 updated by: Antonio Paoli, University of Padova

Effects of Exercise Intensity and Rest Intervals on Intracellular Signals and Anabolic Response of Skeletal Muscle to Resistance Training

Resistance training (RT) is one of the most important stimuli for muscle hypertrophy and it plays an important role on weight loss and fatty acid oxidation increase. RT affects anabolic pathways but the differences among various training techniques has been till now were poorly investigated. The aim of this study was to compare the effect of two different intensity of training, high-intensity interval resistance training (HIIRT) and traditional resistance training (TRT), on muscle signalling pathway.

Study Overview

Detailed Description

Nine young healthy subjects performed HIIRT and TRT protocol in two different moments and with different legs. HIIRT technique consisted of three sets of: 6 repetitions at 6RM (6 repetitions maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30" rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets. Biopsies from the vastus lateralis were taken at baseline (pre), immediately (0h) at the end of training, 6 hours (6h) and 24 hours (24h) after training. Western blot and RT-PCR mRNA (Reverse transcriptase-polymerase chain reaction) analysis were performed to assess muscle signalling pathway activation

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Padova, Italy, 35131
        • Nutrition and Exercise Lab, DSB, University of Padova

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 30 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • moderate active
  • experience with resistance training

Exclusion Criteria:

  • history of recent myocardial infarction,
  • severe cardiac arrhythmia,
  • unstable angina,
  • poorly controlled hypertension,
  • poorly controlled diabetes mellitus,
  • frequent or complex ventricular ectopy which might interfere with one's ability to adhere to exercise protocols

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: High Intensity Interval Resistance Training (HIIRT)
HIIRT technique consisted of three sets of: 6 repetitions at 80% 1RM (1 repetition maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30" rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets.
Subjects trained one leg with HIIRT
ACTIVE_COMPARATOR: Traditional Resistance Training (TRT)
TRT protocol performed 3 series of 15 repetitions at 60% 1RM with 75" of rest between sets.
Subjects trained the other leg with HIIRT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pAMPKThr172 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of pAMPKThr172 in skeletal muscle tissue taken by biopsy
24 hours
pERK 1/2Thr202/Tyr204 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of pERK 1/2Thr202/Tyr204 in skeletal muscle tissue taken by biopsy
24 hours
pS6Ser235/236 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of pS6Ser235/236 in skeletal muscle tissue taken by biopsy
24 hours
p4EBP1Thr37/46 in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
measurement of p4EBP1Thr37/46 in skeletal muscle tissue taken by biopsy
24 hours
ACC (acetyl-coenzyme A carboxylase) phosphorylation in skeletal muscle tissue measured by immunoblot
Time Frame: 24 hours
ACC phosphorylation in skeletal muscle tissue taken by biopsy
24 hours
IGF-1 mRNA (messenger ribonucleic acid) in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
IGF-1 mRNA in skeletal muscle tissue taken by biopsy
24 hours
IGF-1ea (insulin like growth factor) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hoursn
IGF-1ea mRNA in skeletal muscle tissue taken by biopsy
24 hoursn
MGF (mechanical growth factor) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
MGF mRNA in skeletal muscle tissue taken by biopsy
24 hours
STARS mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hoursn
STARS mRNA in skeletal muscle tissue taken by biopsy
24 hoursn
Myogenin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Myogenin mRNA in skeletal muscle tissue taken by biopsy
24 hours
IL-6 (interleukin 6) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
IL-6 mRNA in skeletal muscle tissue taken by biopsy
24 hours
PGC1a4 (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 4) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
PGC1a4 mRNA in skeletal muscle tissue taken by biopsy
24 hours
PGC1a (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
PGC1a mRNA in skeletal muscle tissue taken by biopsy
24 hours
Atrogin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Atrogin mRNA in skeletal muscle tissue taken by biopsy
24 hours
Beclin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Beclin mRNA in skeletal muscle tissue taken by biopsy
24 hours
Myostatin mRNA in skeletal muscle tissue measured by Quantitative polymerase chain reaction (qPCR)
Time Frame: 24 hours
Myostatin mRNA in skeletal muscle tissue taken by biopsy
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Antonio Paoli, MD, University of Padova

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 1, 2012

Primary Completion (ACTUAL)

May 15, 2012

Study Completion (ACTUAL)

February 10, 2013

Study Registration Dates

First Submitted

March 19, 2020

First Submitted That Met QC Criteria

March 24, 2020

First Posted (ACTUAL)

March 25, 2020

Study Record Updates

Last Update Posted (ACTUAL)

March 25, 2020

Last Update Submitted That Met QC Criteria

March 24, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • HIIRT12

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise

Clinical Trials on High Intensity Interval Resistance Training

3
Subscribe